[go: up one dir, main page]

MX2016005233A - Sonda de formacion de imagenes para tau. - Google Patents

Sonda de formacion de imagenes para tau.

Info

Publication number
MX2016005233A
MX2016005233A MX2016005233A MX2016005233A MX2016005233A MX 2016005233 A MX2016005233 A MX 2016005233A MX 2016005233 A MX2016005233 A MX 2016005233A MX 2016005233 A MX2016005233 A MX 2016005233A MX 2016005233 A MX2016005233 A MX 2016005233A
Authority
MX
Mexico
Prior art keywords
imaging probe
tau
tau imaging
formula
low
Prior art date
Application number
MX2016005233A
Other languages
English (en)
Inventor
Yukitsuka Kudo
Nobuyuki Okamura
FURUMOTO Shozo
Original Assignee
Clino Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clino Ltd filed Critical Clino Ltd
Publication of MX2016005233A publication Critical patent/MX2016005233A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un objetivo de la presente invención es proporcionar un compuesto representado por la fórmula (I) que es altamente específico a tau y puede formar imágenes de tau con sensibilidad satisfactoria, y también tiene alta transición cefálica, propiedades de búsqueda de huesos bajas o no reconocidas y toxicidad baja o no detectada. (ver Fórmula).
MX2016005233A 2013-10-22 2014-10-22 Sonda de formacion de imagenes para tau. MX2016005233A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013233470 2013-10-22
PCT/JP2014/078146 WO2015060365A1 (ja) 2013-10-22 2014-10-22 タウイメージングプローブ

Publications (1)

Publication Number Publication Date
MX2016005233A true MX2016005233A (es) 2017-01-05

Family

ID=52992954

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005233A MX2016005233A (es) 2013-10-22 2014-10-22 Sonda de formacion de imagenes para tau.

Country Status (13)

Country Link
US (1) US20160244411A1 (es)
EP (1) EP3061748A4 (es)
JP (1) JPWO2015060365A1 (es)
KR (1) KR20160072226A (es)
CN (1) CN105814023A (es)
AU (1) AU2014338155B2 (es)
BR (1) BR112016008871A8 (es)
CA (1) CA2928313A1 (es)
IL (1) IL245221A0 (es)
MX (1) MX2016005233A (es)
RU (1) RU2016119524A (es)
SG (2) SG11201603131RA (es)
WO (1) WO2015060365A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522414D0 (en) * 2015-12-18 2016-02-03 Clino Ltd Monoamine oxidase B binders
ES2846833T3 (es) 2016-07-18 2021-07-29 Janssen Pharmaceutica Nv Ligandos de obtención de imágenes de tau por PET
ES2965049T3 (es) * 2017-07-12 2024-04-10 Dana Farber Cancer Inst Inc Compuestos para la degradación de la proteína tau
CN107488144B (zh) * 2017-08-09 2021-06-04 复旦大学 一种可以特异性结合并能抑制Tau蛋白聚集的分子及其制备方法和应用
JP7284490B2 (ja) 2018-08-07 2023-05-31 国立大学法人東北大学 モノアミンオキシダーゼｂイメージングプローブ
KR102344676B1 (ko) 2020-02-12 2021-12-30 한국과학기술연구원 타우 응집체에 선택적으로 결합하는 근적외선 형광 탐침자로서 유효한 신규 화합물 및 이의 제조방법
KR102369838B1 (ko) * 2020-04-16 2022-03-04 연세대학교 산학협력단 퀴놀린 유도체를 유효성분으로 포함하는 성상교세포증 관련 질환의 병변 경계부 검출용 조영제 조성물
KR20210128125A (ko) * 2020-04-16 2021-10-26 연세대학교 산학협력단 퀴놀린 유도체를 유효성분으로 포함하는 퇴행성 뇌질환에 의한 치매의 병변 경계부 검출용 조영제 조성물
CN111892534A (zh) * 2020-08-04 2020-11-06 中国科学技术大学 一种pH敏感的荧光探针、其制备方法及其应用
CN113754583A (zh) * 2021-09-03 2021-12-07 湖南工程学院 2-([2，2′-联喹啉基]-3-醚基)-1-乙醇及其衍生物及合成方法
CN113999172A (zh) * 2021-11-17 2022-02-01 湖南工程学院 2-((2-苯基喹啉-3-基)醚基)-1-乙醇及其衍生物及合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2465554A1 (en) * 2002-12-16 2004-06-16 Bf Research Institute, Inc. Quinoline derivatives as probes for the diagnosis of diseases in which tau protein accumulates
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
EP2411057B1 (en) * 2009-03-23 2020-05-06 Eli Lilly and Company Imaging agents for detecting neurological disorders
US8483197B2 (en) * 2009-03-23 2013-07-09 Qualcomm Incorporated AP to legacy station SDMA protocol
KR101101977B1 (ko) 2009-04-09 2012-01-02 (주)에스메디 2-아릴나프탈렌, 2-아릴퀴놀린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
KR20140053811A (ko) 2010-10-29 2014-05-08 클리노 가부시끼가이샤 타우 이미징 프로브
CN103298789A (zh) * 2010-11-16 2013-09-11 通用电气健康护理有限公司 作为τ蛋白病理成像探针的杂环化合物
GB201411571D0 (en) * 2014-06-30 2014-08-13 Ge Healthcare Ltd Radiolabelling method

Also Published As

Publication number Publication date
US20160244411A1 (en) 2016-08-25
SG11201603131RA (en) 2016-05-30
CA2928313A1 (en) 2015-04-30
KR20160072226A (ko) 2016-06-22
SG10201803294PA (en) 2018-06-28
IL245221A0 (en) 2016-06-30
RU2016119524A (ru) 2017-11-28
AU2014338155A1 (en) 2016-05-19
CN105814023A (zh) 2016-07-27
JPWO2015060365A1 (ja) 2017-03-09
EP3061748A1 (en) 2016-08-31
WO2015060365A1 (ja) 2015-04-30
EP3061748A4 (en) 2017-04-05
AU2014338155B2 (en) 2018-08-23
RU2016119524A3 (es) 2018-06-14
BR112016008871A8 (pt) 2020-03-24

Similar Documents

Publication Publication Date Title
MX2016005233A (es) Sonda de formacion de imagenes para tau.
EA201692219A1 (ru) Способы получения противовирусных соединений
PH12015501934A1 (en) New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
JO3433B1 (ar) حلقة كاربوكسامايد ذات أربع أعضاء للاستخدام كمبيدات النيماتودا
IN2014DN09346A (es)
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
EA201591349A1 (ru) Способ получения вортиоксетина
MY176221A (en) Functionalized polymer composition
AR095097A1 (es) Compuestos de fenoxietoxi
MX2018016082A (es) Compuestos quelatos.
MX2016004393A (es) Derivados de carboxamida como compuestos pesticidas.
PH12016500144A1 (en) Imidazothia(dia)zole sulfonamides as nematicides
MX2016012652A (es) Eteraminas a base de 1,2-dialcoholes.
AR124083A2 (es) Nuevo inhibidor de sglt1
MX2015014470A (es) Analogos de combretastatina.
ES2670477R1 (es) Procedimiento para la preparacion de la 17beta-hidroxi-des-a-androst-9,10-en-5-ona
EA201591449A1 (ru) Способы получения противораковых композиций
MX2016000487A (es) Piridina-2-carboxamidas como nematicidas.
IN2013MU01219A (es)
AR095353A1 (es) Compuesto
MX2015009377A (es) Compuestos radiomarcados.
IN2013MU04030A (es)
RU2011107831A (ru) 2-алкил-4,6-диметил-5-оксипиримидины, обладающие противоопухолевым и иммуномодулирующим действием